Tempest Therapeutics, Inc. (TPST) — Financial statements
Income statement, balance sheet, and cash flow for Tempest Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.39 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -0.39 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↓55.7% | 28↑62.7% | 17↓22.3% | 23↑31.2% | 17 | |
| General & Administrative Expenses | 14↑3.1% | 14↑16.2% | 12↓3.7% | 12↑23.4% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↑3.1% | 14↑16.2% | 12↓3.7% | 12↑23.4% | 10 | |
| Other Expenses | 0.00↑100.0% | -0.39 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 27↓36.2% | 42↑42.8% | 29↓15.8% | 35↑28.4% | 27 | |
| Total Costs & Expenses | 27↓36.8% | 42↑44.1% | 29↓15.8% | 35↑28.4% | 27 | |
| Operating Results | ||||||
| Operating Income | -27↑36.8% | -42↓44.1% | -29↑15.8% | -35↓28.4% | -27 | |
| Depreciation & Amortization | 0.27↓31.6% | 0.39↑2.1% | 0.38↓40.3% | 0.64↑70.6% | 0.37 | |
| EBITDA | -26↑35.7% | -40↓45.1% | -28↑17.3% | -33↓25.5% | -27 | |
| EBIT | -26↑35.7% | -41↓44.5% | -28↑17.7% | -34↓26.2% | -27 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.31↑71.0% | 0.18↑154.8% | -0.33↑68.8% | -1↑16.5% | -1 | |
| Interest Income | 0.52↓65.3% | 1↑34.4% | 1↑103.1% | 0.55↑42723.7% | 0.00 | |
| Interest Expense | 0.21↓84.3% | 1↓9.2% | 1↓10.4% | 2↑26.2% | 1 | |
| Non-Operating Income | -0.52↑65.3% | -1↓34.4% | -1↓103.1% | -0.55↓1714.7% | 0.03 | |
| Other Income / Expenses | 0.31↑71.0% | 0.18↑154.8% | -0.33↑68.8% | -1↑18.8% | -1 | |
| Income Before Tax | -26↑37.2% | -42↓41.9% | -29↑17.4% | -36↓26.2% | -28 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -26↑37.2% | -42↓41.9% | -29↑17.4% | -36↓26.2% | -28 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -26↑37.2% | -42↓41.9% | -29↑17.4% | -36↓26.2% | -28 | |
| Bottom-Line Net Income | -26↑37.2% | -42↓41.9% | -29↑17.4% | -36↓26.2% | -28 | |
| EPS (Basic) | -6.33↓322.0% | -1.50↑21.5% | -1.91↑39.9% | -3.18↑59.2% | -7.80 | |
| EPS (Diluted) | -6.33↓322.0% | -1.50↑21.5% | -1.91↑39.9% | -3.18↑59.2% | -7.80 | |
| Weighted Average Shares | 4↓85.1% | 28↑81.0% | 15↑1636.1% | 0.89↑205.2% | 0.29 | |
| Weighted Average Diluted Shares | 4↓85.1% | 28↑81.0% | 15↑1635.3% | 0.89↑204.7% | 0.29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.